← All diseases Liver, kidneys and digestion

Fatty liver disease (MASH/NASH), advanced

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest evidence only (129)Meta-analysis (42)Randomized Trial (40)Systematic review (32)Phase 3 Study (15)Clinical trial (222)Review article (430)Early study (phase 1 or 2) (12)Laboratory or Animal Study (273)Single Patient Description (18)Commentary or Editorial (50)Retracted Publication (4) Studies currently seeking participants only (40)

Filter

Publications and studies (2544)

• Commentary or editorialiAn expert's opinion or commentary, not new research. Exploring non-invasive diagnostics and non-imaging approaches for pediatric metabolic dysfunction-associated steatotic liver disease. (2024/12/21) ♡
• Carnitine palmitoyltransferase-II inactivity promotes malignant progression of metabolic dysfunction-associated fatty liver disease via liver cancer stem cell activation. (2024/12/21) ♡
• Assessment of Non-alcoholic Fatty Liver Disease and Level of Risk of Fibrosis in Diabetic and Non-diabetic Individuals. (2024/12/21) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. [Exocarpium Citri Grandis formula granules alleviate fatty liver disease in Zebrafish by maintaining iron homeostasis and suppressing lipid peroxidation and ferroptosis]. (2024/12/20) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Ruptured hepatocellular carcinoma developed in a normal liver in a young patient with a body mass index of 33 kg/m(2). (2024/12/20) ♡
• Exploring the mechanism of berberine treatment for atherosclerosis combined with non-alcoholic fatty liver disease based on bioinformatic and experimental study. (2024/12/19) ♡
• Association between composite dietary antioxidant index and metabolic dysfunction-associated fatty liver disease: a cross-sectional study from NHANES. (2024/12/19) ♡
• Copper status and its relation to abdominal obesity indices and liver function in non-alcoholic fatty liver disease: a case-control study. (2024/12/19) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Steatotic liver disease arising in an asymptomatic 20-year-old man with panhypopituitarism and elevated transaminases. (2024/12/19) ♡
• Comparison of the magnetic resonance elastography and FIB-4 (MEFIB) Index and vibration-controlled transient elastography for significant metabolic dysfunction-associated steatotic liver disease fibrosis. (2024/12/19) ♡
• The plasma lipidome varies with the severity of metabolic dysfunction-associated steatotic liver disease. (2024/12/18) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. The impact of a short-term high-fat diet on coagulation function in a mouse model and its role in exacerbating concanavalin A-induced liver injury. (2024/12/18) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. [Hepatocellular carcinoma (HCC)]. (2024/12/18) ♡
• RAP1A suppresses hepatic steatosis by regulating amino acid-mediated mTORC1 activation. (2024/12/18) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. 6-Gingerol, a Bioactive Compound of Zingiber officinale, Ameliorates High-Fat High-Fructose Diet-Induced Non-Alcoholic Related Fatty Liver Disease in Rats. (2024/12/17) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. A Moderate Intake of Beer Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a High-Fat Diet (HFD)-Induced Mouse Model. (2024/12/17) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Molecular Pathways Linking High-Fat Diet and PM(2.5) Exposure to Metabolically Abnormal Obesity: A Systematic Review and Meta-Analysis. (2024/12/16) ♡
• Deep phenotyping of patients with MASLD upon high-intensity interval training. (2024/12/16) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Fanlian Huazhuo Formula: A promising herbal preparation for metabolic liver disease. (2024/12/14) ♡
• Duodenal Organoids From Metabolic Dysfunction-Associated Steatohepatitis Patients Exhibit Absorptive and Barrier Alterations. (2024/12/12) ♡
• The Midlands Liver Research Alliance - A partnership to optimise obesity-related liver disease research: targeting areas of high incidence and underserved communities. (2024/12/12) ♡
• The Effect of Quercetin on Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Beclin1, P62, and LC3: An Experimental Study. (2024/12/11) ♡
• Prevalence and Prognostic Significance of Malnutrition in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD). (2024/12/11) ♡
• Lactobacillus delbrueckii subsp. lactis CKDB001 Ameliorates Metabolic Complications in High-Fat Diet-Induced Obese Mice. (2024/12/10) ♡
• Long-Term Aerobic Exercise Enhances Hepatoprotection in MAFLD by Modulating Exosomal miR-324 via ROCK1. (2024/12/09) ♡
• Effect of Dendrobium nobile powder combined with conventional therapy on mild to moderate fatty liver. (2024/12/07) ♡
• Body mass index and waist-to-height ratio effect on mortality in non-alcoholic fatty liver: revisiting the obesity paradox. (2024/12/06) ♡
• TFEB activator tanshinone IIA and derivatives derived from Salvia miltiorrhiza Bge. Attenuate hepatic steatosis and insulin resistance. (2024/12/05) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Yogurt Supplementation Can Ameliorate Fatty Liver Diseases and Metabolic Syndrome in High Fat-Induced Conditions in Mice. (2024/12/05) ♡
• Active Targets and Potential Mechanisms of Erhuang Quzhi Formula in Treating NAFLD: Network Analysis and Experimental Assessment. (2024/12/01) ♡
• Multi-omics joint analysis reveals that the Miao medicine Yindanxinnaotong formula attenuates non-alcoholic fatty liver disease. (2024/12/01) ♡
• Systematic reviewiAll research on one question is searched according to fixed rules and compared side by side, so that no studies with poor outcomes are missed. Comparative effectiveness of five Chinese patent medicines for non-alcoholic fatty liver disease: A systematic review and Bayesian network meta-analysis. (2024/12/01) ♡
• Synthesis and biological evaluation of quinoxaline derivatives as ASK1 inhibitors. (2024/12/01) ♡
• Dietary supplement of veratric acid alleviates liver steatosis and reduces abdominal fat deposition in broilers. (2024/12/01) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Garcinol enriched fraction of Garcinia morella (Gaertn.) Desr. fruit rind improves gut health and reduces the risk of nonalcoholic fatty liver disease by regulating PCK1/ACC/SREBP1/FASn pathway in a mouse model. (2024/12/01) ♡
• Once-Monthly Efimosfermin Alfa (BOS-580) in Metabolic Dysfunction-Associated Steatohepatitis With F2/F3 Fibrosis: Results From a 24-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial. (2024/12/01) ♡
• Phase 3 ESSENCE Trial: Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. (2024/12/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. The Impact of Sira Vedha (Phlebotomy) at the Right Elbow Joint in the Treatment of Non-Alcoholic Fatty Liver Disease - A Research Report. (2024/12/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. MASH to cirrhosis: bridging the gaps in MASLD management. (2024/12/01) ♡
• Metabolic associated steatotic liver disease misses fewer high-risk patients than metabolic associated fatty liver disease. (2024/12/01) ♡
• Shared Genetic Links Between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease. (2024/11/26) ♡
• High levels of serum dihomo-γ-linolenic acid are associated with non-alcoholic fatty liver disease in type 2 diabetic patients. (2024/11/23) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Liver disease-linked metabolic and behavioral factors associated with cognitive performance in an observational study of community dwelling adults. (2024/11/22) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Potential of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease: A promising future. (2024/11/21) ♡
• Steatotic Liver Disease Education Enhances Knowledge and Confidence to Adhere to Provider Recommendations in Diverse and Vulnerable Populations. (2024/11/20) ♡
• Validation of the Chronic Liver Disease Questionnaire for MASH (CLDQ-MASH). (2024/11/16) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Efficacy and safety of electroacupuncture for metabolic dysfunction-associated fatty liver disease: a study protocol for a multicentre, randomised, sham acupuncture-controlled, patient-blinded clinical trial. (2024/11/14) ♡
• Global burden of metabolic dysfunction-associated steatotic liver disease, 2010 to 2021. (2024/11/14) ♡
• Protective Effect of Modified Suanmei-Tang on Metabolic-Associated Fatty Liver Disease: An Integrated Strategy of Network Pharmacology, Metabolomics, and Transcriptomics. (2024/11/13) ♡
• Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. PAMK Ameliorates Non-Alcoholic Steatohepatitis and Associated Anxiety/Depression-like Behaviors Through Restoring Gut Microbiota and Metabolites in Mice. (2024/11/08) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.